Anthera Pharmaceuticals 

We are focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs.

Find out more about what we are doing for patients with Cystic Fibrosis, Systemic Lupus Erythematosus, and IgA Nephropathy:

Cystic Fibrosis
Systemic Lupus Erythematosus
IgAN

ANTH on NASDAQ

LATEST NEWS

Anthera Pharmaceuticals Announces Leadership Transition in Preparation of Commercialization of Sollpura and Future Development of Blisibimod for IgA Nephropathy. Read more

Anthera Pharmaceuticals Announces that the Blisibimod BRIGHT-SC Phase 2 Study Continues to Demonstrate Positive Trends in the Week 48 Analysis. Read more

UPCOMING EVENTS

2016 Annual Piper Jaffray Healthcare Conference
November 30, 2016

2016 Citi Global Healthcare Conference
December 7-8, 2016

Print Friendly